Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

19.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.8K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

16.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
16.6K
T Cell Types and Functions01:24

T Cell Types and Functions

2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CpG-induced immune responses <i>via</i> DNA micelles, gold nanoparticles, and liposomes.

Nanoscale horizons·2025
Same author

Mucin-Inspired Filamentous Sulfated Copolymers Effectively Inhibit Human Respiratory Syncytial Virus (hRSV) Infectivity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Size-Dependent Ultrasound Activation of Thrombin Catalytic Activity by Mechano-Nanoswitches.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Microbubble Shell Stiffness Engineering Enhances Ultrasound Imaging, Drug Delivery, and Sonoporation.

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

Modular Design of Hydrogel Adhesives for Enhanced Tissue Healing.

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

Minimally Invasive DNA-Mediated Photostabilization for Extended Single-Molecule and Super-resolution Imaging.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Feb 26, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

853

CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Andreas Herrmann1, Christoph Lahtz2, Toshikage Nagao2,3

  • 1Department of Onco-Immunology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California. aherrmann@coh.org hyu@coh.org.

Cancer Research
|July 19, 2017
PubMed
Summary

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) plays a critical role in B-cell lymphoma proliferation and survival by activating the Tyk2-STAT3 pathway. Blocking CTLA4 inhibits tumor growth and induces apoptosis, revealing new therapeutic targets.

More Related Videos

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia
09:43

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Published on: June 9, 2023

2.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

853
Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia
09:43

Co-Culture and Transduction of Murine Thymocytes on Delta-Like 4-Expressing Stromal Cells to Study Oncogenes in T-Cell Leukemia

Published on: June 9, 2023

2.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is a known immune checkpoint primarily inhibiting T-cell responses.
  • Its protumorigenic role was thought to be solely through counteracting T-cell costimulation via CD28.
  • CTLA4 overexpression is observed in B-cell lymphomas and melanoma-associated B cells.

Purpose of the Study:

  • To investigate additional roles of CTLA4 in cancer beyond T-cell inhibition.
  • To elucidate the molecular mechanisms underlying CTLA4's protumorigenic function in B-cell malignancies.
  • To assess the therapeutic potential of targeting CTLA4 in B-cell lymphomas.

Main Methods:

  • Investigated CTLA4 signaling pathways in B-cell lymphoma and melanoma models.
  • Utilized CTLA4 silencing and antibody blockade in tumor cells.
  • Assessed Tyk2/STAT3 activation, cell proliferation, and apoptosis.

Main Results:

  • CTLA4-CD86 ligation activates Tyk2 and STAT3, promoting immunosuppression and tumor growth.
  • CTLA4 blockade in B-cell lymphoma cells inhibited tumor growth, reduced Tyk2/STAT3 activity, and induced apoptosis, independent of T cells.
  • The CTLA4-Tyk2-STAT3 pathway is active in both malignant and non-malignant B cells in cancer models.

Conclusions:

  • CTLA4 promotes B-cell lymphoma proliferation and survival through an intrinsic Tyk2-STAT3 pathway.
  • CTLA4's function extends beyond T-cell inhibition, impacting B-cell malignancies directly.
  • Targeting the CTLA4-Tyk2-STAT3 axis presents a promising therapeutic strategy for B-cell lymphomas.